Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase

Kim, Jong‐Eun; Kim, Jaehwan; Lee, Younghyun; Yang, Hee Seok; Heo, Yong Seok; Bode, Ann M.; Lee, Ki Won; Dong, Zigang

doi:10.18632/oncotarget.7524

Cited by 42 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bak is a meroterpene found in the traditional Chinese herbal medicine Fructus psoraleae [ 8 ]. Kim et al [ 18 ] found that Bak exhibits potent anti-cancer activity by directly targeting Blk, Hck, and p38 MAPK. Shoji et al [ 19 ] reported that Bak produced enantiomer-selective anti-influenza A virus activity via a novel mechanism involving the host-cell response, which contributes to the development of novel approaches for the treatment of influenza.…”

Section: Discussionmentioning

confidence: 99%

Bakuchiol protects against pathological cardiac hypertrophy by blocking NF-κB signaling pathway

et al. 2018

View full text Add to dashboard Cite

Bakuchiol (Bak), a monoterpene phenol isolated from the seeds of Psoralea corylifolia, has been widely used to treat a large variety of diseases in both Indian and Chinese folkloric medicine. However, the effects of Bak on cardiac hypertrophy remain unclear. Therefore, the present study was designed to determine whether Bak could alleviate cardiac hypertrophy. Mice were subjected to aortic banding (AB) to induce cardiac hypertrophy model. Bak of 1 ml/100 g body weight was given by oral gavage once a day from 1 to 8 weeks after surgery. Our data demonstrated for the first time that Bak could attenuate pressure overload-induced cardiac hypertrophy and could attenuate fibrosis and the inflammatory response induced by AB. The results further revealed that the effect of Bak on cardiac hypertrophy was mediated by blocking the activation of the NF-κB signaling pathway. In vitro studies performed in neonatal rat cardiomyocytes further proved that the protective effect of Bak on cardiac hypertrophy is largely dependent on the NF-κB pathway. Based on our results, Bak shows profound potential for its application in the treatment of pathological cardiac hypertrophy, and we believe that Bak may be a promising therapeutic candidate to treat cardiac hypertrophy and heart failure.

show abstract

Section: Discussionmentioning

confidence: 99%

Bakuchiol protects against pathological cardiac hypertrophy by blocking NF-κB signaling pathway

et al. 2018

View full text Add to dashboard Cite

show abstract

“…After 24 h, A431 cells were selected with 2 μg/mL of puromycin. The shMock or shPRPK -transfected A431 cells were incubated for 10 days as described previously ( 53 ). Colony formation was observed and analyzed using a LEICA DM IRB microscope (Nikon Corporation) and the ImagePro Plus software (v.6.1) program (Media Cybernetics Inc., Rockville, MD).…”

Section: Methodsmentioning

confidence: 99%

Targeting PRPK and TOPK for skin cancer prevention and therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

Solar ultraviolet (sUV) irradiation is a major environmental carcinogen that can cause inflammation and skin cancer. The costs and morbidity associated with skin cancer are increasing, and therefore identifying molecules that can help prevent skin carcinogenesis is important. In this study, we identified the p53-related protein kinase (PRPK) as a novel oncogenic protein that is phosphorylated by the T-LAK cell-originated protein kinase (TOPK). Knockdown of TOPK inhibited PRPK phosphorylation and conferred resistance to solar simulated light (SSL)-induced skin carcinogenesis in mouse models. In the clinic, acute SSL irradiation significantly increased epidermal thickness as well as total protein and phosphorylation levels of TOPK and PRPK in human skin tissues. We identified two PRPK inhibitors, FDA-approved rocuronium bromide (Zemuron®) or betamethasone 17-valerate (Betaderm®) that could attenuate TOPK-dependent PRPK signaling. Importantly, topical application of either rocuronium bromide or betamethasone decreased SSL-induced epidermal hyperplasia, neovascularization and cutaneous squamous cell carcinoma (cSCC) development in SKH1 (Crl: SKH1-Hrhr) hairless mice by inhibiting PRPK activation, and also reduced expression of the proliferation and oncogenesis markers, COX-2, cyclin D1 and MMP-9. This study is the first to demonstrate that targeting PRPK could be useful against sUV-induced cSCC development.

show abstract

“…Other members of SFKs could be involved in specific steps of skin cancer progression. Kim et al showed that the EGF-stimulated anchorage-independent growth of A431 human epidermoid carcinoma cells could be inhibited by blocking the kinase activity of Hck and Blk [110].…”

Section: Other Cancersmentioning

confidence: 99%

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far

Martellucci

Clementi

Sabetta

et al. 2020

Cancers

View full text Add to dashboard Cite

Src is the prototypal member of Src Family tyrosine Kinases (SFKs), a large non-receptor kinase class that controls multiple signaling pathways in animal cells. SFKs activation is necessary for the mitogenic signal from many growth factors, but also for the acquisition of migratory and invasive phenotype. Indeed, oncogenic activation of SFKs has been demonstrated to play an important role in solid cancers; promoting tumor growth and formation of distant metastases. Several drugs targeting SFKs have been developed and tested in preclinical models and many of them have successfully reached clinical use in hematologic cancers. Although in solid tumors SFKs inhibitors have consistently confirmed their ability in blocking cancer cell progression in several experimental models; their utilization in clinical trials has unveiled unexpected complications against an effective utilization in patients. In this review, we summarize basic molecular mechanisms involving SFKs in cancer spreading and metastasization; and discuss preclinical and clinical data highlighting the main challenges for their future application as therapeutic targets in solid cancer progression

show abstract

Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase

Cited by 42 publications

References 34 publications

Bakuchiol protects against pathological cardiac hypertrophy by blocking NF-κB signaling pathway

Bakuchiol protects against pathological cardiac hypertrophy by blocking NF-κB signaling pathway

Targeting PRPK and TOPK for skin cancer prevention and therapy

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far

Contact Info

Product

Resources

About